Unicorn Nest news
Coave Therapeutics Closes €33M in Series B Financing
– Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B funding round, bringing the total raised to €33.1m ($39m).
– This round was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
– The company will use the proceeds to support the execution of its corporate strategy, which is focused on advancing its lead clinical program CTx-PDE6b for the treatment of PDE6b inherited retinal dystrophies, currently in Phase I/II clinical trial, towards pivotal trials, developing its AAV Ligand Conjugate (‘ALIGATER’) platform, which is designed to enhance the delivery and efficiency of AAV vectors via a proprietary chemical conjugation technology to produce targeted gene therapy products, advancing new preclinical programs, based on AAV-Ligand Conjugate capsids (coAAV), in rare CNS and Ocular diseases, including CTx-GBA1 for Parkinson’s disease and Gaucher Disease and CTx-ABCA4 for Stargardt’s disease, entering partnerships in key disease areas to progress novel coAAV candidates towards the clinic and to address other disease areas given the potential of the platform and the scope for targeting other tissues.
Unicorn Nest news
Elistair, The Pioneer in Tethered UAVs, Announces a €5M Series B Round to Accelerate Its International Expansion
– Elistair, a market leader in tethered drones, has raised €5M from Omnes and Starquest Capital, its historic investor.
– This Series B round follows an initial €2M funding round in 2018.
– Elistair counts national security and defense organizations amongst its customers, offering them two patented product ranges: an automated tethered drone: Orion 2 and tether stations capable of transforming free-flying drones into tethered drones.
– The Orion 2 drone acts as an aerial reconnaissance mast, substantially increasing the field of vision of operating forces and reducing vulnerable entry points.
– They are also used to deploy tactical communication networks, greatly increasing the range and coverage of military radios.
Unicorn Nest news
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
– AgomAb Therapeutics N.V. announced today the closing of a $74m Series B financing round led by Redmile Group, with participation from Cormorant Asset Management.
– All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures.
– The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies.
– The capital will also support further growth of the company’s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases.